冷藏大隐静脉同种异体移植物用于下肢动脉疾病的回顾性多中心评估(REVAS研究)
结果显示移植物相关并发症达54.0%,5年一期通畅率36.5%、二期通畅率44.5%,5年免于大截肢率61.5%,多节段移植物与并发症增加及通畅率下降独立相关。
要点
- CSVA中期通畅有限、再干预负担重,仅限严格选择的挽救性场景使用。
- 移植物相关并发症54.0%,以旁路闭塞(46.5%)最常见。
- 多节段移植物与移植物相关并发症增加及一期通畅率下降独立相关。
核心结论
- 在缺乏合适自体导管和持久腔内治疗选择的患者中,CSVA可提供有意义的保肢效果,但通畅率有限且再干预负担大。
- 其使用应限于经过仔细选择的挽救性场景,并配合结构化随访。
研究设计与样本
- 法国四中心回顾性多中心研究,纳入2018年1月至2024年2月连续接受腹股沟下旁路并使用+4°C冷藏大隐静脉同种异体移植物的患者。
- 主要终点为移植物相关并发症(动脉瘤样退变、移植物感染、破裂、闭塞);次要终点包括一期与二期通畅率、主要不良肢体事件(MALE)、保肢、再干预与生存。
- 采用Kaplan-Meier法和多因素回归分析,平均随访24个月。
主要发现
- 手术指征:慢性肢体威胁性缺血131条(65.5%)、慢加急性缺血26条(13.0%)、致残性间歇性跛行24条(12.0%)、血管移植物感染28条(13.7%)。
- 膝下靶血管150条(75.0%),再次血运重建131条(65.5%)。
- 移植物相关并发症108条(54.0%),其中旁路闭塞93条(46.5%)、破裂15条(7.5%)、动脉瘤样退变11条(5.5%)、假性动脉瘤5条(2.5%)、移植物感染8条(4.0%)。
- 主要再干预88条(44.0%),主要不良肢体事件104条(52.0%)。
- 一期通畅率1年59.5%(95%CI 51.5-66.5)、5年36.5%(95%CI 27.5-45.5);二期通畅率1年64.1%(95%CI 56.2-71.0)、5年44.5%(95%CI 35.0-53.6);免于大截肢率1年75.0%、5年61.5%。
关键数值与推荐
- 多节段移植物120条(60.0%)与移植物相关并发症增加独立相关(校正OR 2.27;95%CI 1.44-3.69)。
- 多节段移植物与一期通畅率下降独立相关(校正HR 1.35;95%CI 1.02-1.77)。
临床怎么用
- 在无合适自体静脉且腔内治疗不持久的患者中,可将CSVA作为保肢的挽救性生物导管。
- 应限制用于经过仔细选择的病例,并配合结构化随访监测闭塞、破裂与移植物感染。
局限性
- 本研究为回顾性多中心设计。
- 平均随访时间为24个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Autologous great saphenous vein remains the reference conduit for infrainguinal bypass, but is unavailable or unsuitable in a substantial proportion of patients. In complex redo reconstructions, infrageniculate targets, or infected fields, alternative options (arm veins or endovascular reconstructions) may also be limited. Cold-stored venous allografts (CSVAs) represent a biological salvage conduit in such settings, although concerns persist regarding durability. This study evaluated the midterm outcomes of infrainguinal bypass using CSVA in routine practice. METHODS: This retrospective multicenter study included consecutive patients undergoing infrainguinal bypass with cold-stored great saphenous vein allografts (+4°C) between January 2018 and February 2024 across four French centers. Indications included chronic limb-threatening ischemia, disabling claudication, acute-on-chronic ischemia, and vascular prosthesis infection. The primary end point was graft-related complications (aneurysmal degeneration, graft infection, rupture, occlusion). Secondary end points included primary and secondary patency, major adverse limb events (MALEs), limb salvage, reinterventions, and survival. Kaplan-Meier methods and multivariable regression analyses were performed. RESULTS: Two hundred lower limbs (195 patients; mean age 70 ± 11 years; 159 men [79.5%]) were included. Indications were chronic limb-threatening ischemia in 131 (65.5%), acute-on-chronic ischemia in 26 (13.0%), disabling claudication in 24 (12.0%), and vascular prosthesis infection in 28 (13.7%). Infrageniculate targets were used in 150 (75.0%) and redo revascularization was performed in 131 (65.5%). The mean follow-up was 24 months. Graft-related complications occurred in 108 (54.0%), including bypass occlusion in 93 (46.5%), rupture in 15 (7.5%), aneurysmal degeneration in 11 (5.5%), pseudoaneurysm in 5 (2.5%), and graft infection in 8 (4.0%). Major reinterventions were required in 88 (44.0%), and major adverse limb events occurred in 104 (52.0%). Primary patency was 59.5% (95% confidence interval [CI], 51.5-66.5) at 1 year and 36.5% (95% CI, 27.5-45.5) at 5 years; secondary patency was 64.1% (95% CI, 56.2-71.0) at 1 year and 44.5% (95% CI, 35.0-53.6) at 5 years. Freedom from major amputation was 75.0% at 1 year and 61.5% at 5 years. Multiple segment grafts (120 [60.0%]) were independently associated with increased graft-related complications (adjusted odds ratio, 2.27; 95% CI, 1.44-3.69) and reduced primary patency (adjusted HR 1.35; 95% CI, 1.02-1.77). CONCLUSIONS: In patients lacking suitable autologous conduit and durable endovascular options, CSVAs provide meaningful limb salvage, but are associated with limited patency and substantial reintervention burden. Their use should remain restricted to carefully selected salvage scenarios with structured surveillance.
引用
- Coatsaliou Q, Canonge J, Beaucarne T, et al. Retrospective multicenter Evaluation of cold-stored saphenous Vein Allografts in peripheral arterial diSease (REVAS study). J Vasc Surg. 2026. PMID: 41833588. doi:10.1016/j.jvs.2026.03.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。